Figure
Download
View publication
Summary of current and pipeline NLRP3 inhibitors.

Summary of current and pipeline NLRP3 inhibitors.

Source publication
Figure 1: NLRP3 inflammasome two-step activation: The first priming...
Summary of IL-1β inhibitors.
Summary of current and pipeline NLRP3 inhibitors.
The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors
Article
Full-text available
  • Nov 2019
Coronary Artery Disease (CAD) represents a major health burden worldwide. It is driven by chronic inflammation of the arterial vasculature supplying the heart, in response to pro-inflammatory assaults such as high LDL cholesterol. The resultant atherosclerosis can cause occlusive disease and acute cardiovascular events. The pro-inflammatory cytokin...
Cite
Download full-text

Context in source publication

Context 1
... can, however, be more expensive to produce and cell penetrability can be an issue [61,62]. There are reports of novel ways being developed to assist entry of antibodies inside the cell [63] ( Table 2). ...

Similar publications

Kaplan–Meier curve. Diabetic patients. Total events = 56. Galectin-3...
Characteristics of patients with and without diabetes.
Cox proportional hazards model for the incidence of acute ischemic...
Cox proportional hazards model for the incidence of acute ischemic events.
Cox proportional hazards model for the incidence of heart failure or death.
Galectin-3 Is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes
Article
Full-text available
  • Apr 2020
Introduction: Type-2 diabetes mellitus (T2DM) is associated with early and severe atherosclerosis. However, few biomarkers can predict cardiovascular events in this population. Methods: We followed 964 patients with coronary artery disease (CAD), assessing plasma levels of galectin-3, monocyte chemoattractant protein-1 (MCP-1), and N-terminal fr...
View

Citations

Precision medicine to manage chronic immune-related conditions
Chapter
  • Jan 2022
The dysregulated immune system represents a major target for improving health outcomes in a range of chronic conditions. This chapter describes key changes in the immune system as we age and showcases its dysregulation across five chronic conditions including diabetes, cardiovascular disease, and cancer, highlighting dysregulated key immune system pathways and resultant inflammatory sequelae. Precision medicine aims to subdivide patients into different groups who will respond to specific treatments and could offer a novel way of addressing the complexity of immune system involvement in these conditions. The potential for precision medicine-led therapeutic strategies is discussed for each condition and considered in the context of multimorbidity.
View